A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Adaptive Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in Treatment-Naïve Adults Living With HIV-1
Sponsor: ViiV Healthcare
Terminated
Sponsor decision
Other terminated trials from ViiV Healthcare
Other HIV Infections trials with similar outcome
A PHASE2 clinical study on HIV Infections, this trial is terminated or withdrawn. The trial is conducted by ViiV Healthcare and has accumulated 7 data snapshots since 2023. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Nov 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Terminated PHASE2
-
May 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Suspended → Terminated
-
Oct 2024 — May 2025 [monthly]
Suspended PHASE2
Status: Not Yet Recruiting → Suspended
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE2
▶ Show 2 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ViiV Healthcare
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Alicante, Spain , Athens, Greece , Bakersfield, United States , Brescia, Italy , Buenos Aires, Argentina , Dallas, United States , Genova, Italy , Granada, Spain , Jerez de la Frontera, Spain and 7 more locations